Dallas, Texas 04/28/2014 (FINANCIALSTRENDS) – Novavax, Inc. (NASDAQ:NVAX) which is a US based biopharma with clinical stage development has been offering a range of recombinant vaccines.
Novavax, Inc. (NASDAQ:NVAX) has a market capital of 813.23 million and a 52-week trading range of $1.68 and $6.95 high. This stock has an EPS of -0.31 and outstanding shares for this stock are in the region of 209.06 million. Beta for this share is in the region of 2.13.
Novavax, Inc. (NASDAQ:NVAX)has at the start of April seen insider trading by over four executives, resulting in quick and fast movement of the stocks at the markets during those trading sessions.
Novavax, Inc (NASDAQ:NVAX) has since developed differentiated and technology specific platform which allows vaccine technology for the development of virus-like particles or VLPs.
Novavax, Inc. (NASDAQ:NVAX) will going forward look at advanced engineering rounds, such as genetically modified three-dimensional nanostructures. These have now built immunological recombinant proteins where the acquisition is the 97.4% shares which it will offer ISCONOVA AB.
Novavax, Inc. (NASDAQ:NVAX) has thus far been successful with its ‘insect cell culture’ which is the basis of the technology platform it has developed to allow its bioprocessing technology, during the manufacturing process.
Back in 2011, the company has been awarded the contract by the Department of health and Human Services, Biomedical Advanced Research as well as Development Authority or HHS BARDA of the US government.
In the recent times, the US government has also offered 36 month base-period during which it is expected to develop the HHS BARDA option which for the first 24 months considered it as the base-period. The HHS BARDA option period is open for 24 months.